INDIAN BENCHMARK see a negative start on
account of weak global cues. Piramal Enterprises sold the stake comprising 45.4mn
shares of Vodafone India for Rs89bn to Prime Metal, an indirect subsidiary of
Vodafone Plc.
FURTHER, Natco Pharma
Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead
Sciences Inc’s breakthrough hepatitis C drug Sovaldi a patent in India.
Tatas
likely to invest another Rs 2,000 crore in their loss-making wireless telephony
firm as equity within the next two years to service its loans.
Trend in FII flows: The FIIs
were net buyers of Rs.342cr in the cash segment on Thursday while the
domestic institutional investors (DIIs) were net buyers of Rs. 13cr,
as per the provisional figures released by the NSE.
For More Detail Call Us 0731-6790000,6669900
Click Here capitalstars.com
Click Here capitalstars.com
0 comments:
Post a Comment